COMMUNIQUÉS West-GlobeNewswire

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
04/03/2025
Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/03/2025
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board
04/03/2025
GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
04/03/2025
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
IO Biotech Reports 2024 Business Highlights
04/03/2025
Preparations for submission of a Biologics License Application (BLA) for Cylembi o ® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 [...]
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
04/03/2025
THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6 [...]
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
04/03/2025
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/03/2025
CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Sanuwave Health to Uplist to the Nasdaq Global Market
04/03/2025
Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 EDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or "Sanuwave”) (OTCQB: SNWV), a leading provider of next- [...]
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results
04/03/2025
Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue [...]
Arvinas to Participate in Upcoming Investor Conferences
04/03/2025
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
04/03/2025
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/03/2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly- [...]
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
04/03/2025
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net [...]
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease
04/03/2025
Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable tolerability profile [...]
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
04/03/2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
BeautyHealth to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
04/03/2025
LONG BEACH, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report fourth quarter and full year 2024 financial results [...]
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
04/03/2025
Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“ [...]
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
04/03/2025
U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024 [...]

Pages